$2.380
+0.149 (+6.25%)At close
CYCU News
CYCU Events
Cycurion Regains Nasdaq Compliance
Cycurion announced that it has received a letter, dated October 1, 2026, from the Hearings Office of The Nasdaq Stock Market LLC confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(1), the minimum bid price requirement of $1.00 per share, as required by the Nasdaq Hearings Panel's decision letter dated September 9, 2026. "Nasdaq's letter confirms that we met the bid-price condition in the Panel's decision," said Kevin Kelly, Chairman and Chief Executive Officer of Cycurion. "The common stock continues to trade on Nasdaq. We understand the monitor, and meeting Nasdaq's listing standards has been, and remains, a priority for the Company."
Cycurion Resolves John Doe Defamation Case
Cycurion announced that it has resolved the previously disclosed John Doe defamation action in the United States District Court for the Eastern District of Virginia. The defendant, who published under anonymous aliases, has admitted the accusations were false and has signed a retraction and personal apology. "We do not litigate for theater. We said we would pursue the people who used aliases to accuse this Company of crimes it did not commit. We did," said L. Kevin Kelly, Chairman and Chief Executive Officer of Cycurion. "The defendant has retracted those statements in writing and apologized. He is barred from repeating them, barred from trading our stock, and required to cooperate. Words have consequences. So do false ones."
Cycurion Forecasts $843,028 Revenue in 2026
Cycurion announced that closed public safety engagements, including work supporting the City of Chicago, are forecast to generate approximately $843,028 in revenue during calendar 2026. The work includes CAD administration, go-live support and fire-department training.
Cycurion Announces Approximately $800K in Contracts
Cycurion announced several engagements totaling approximately $800K in annual contract spend. The work includes a pharmaceutical-industry engagement to support an AI Center of Excellence, a new award with the National Association of County and City Health Officials, and additional commercial and public-health engagements. This is the first public announcement of these awards. The company is building commercial healthcare and life-sciences work as a primary growth market, while continuing to run its government and public-safety franchise. Scope across the engagements includes business continuity and disaster recovery, technology and cybersecurity assessments, program management, organizational change management, and AI operating capability. The pharmaceutical AI Center of Excellence engagement is a commercial life-sciences win the company has been building toward. The NACCHO award is being announced for the first time and deepens Cycurion's existing relationship with the association, including its standing as a Diamond Affiliate Partner. Additional commercial and public-health work is included in the approximately $800K annual contract-spend total. The company will continue to pursue additional commercial and non-government opportunities that fit its capabilities in cybersecurity, managed IT, program delivery, and AI-enabled transformation.
Cycurion Inc Trading Halted, News Pending
Cycurion Inc trading halted, news pending
Related articles
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

